Research ExplorerPublicationsAnti-acid therapy in SSc-associated interstitial lung diseas...

Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis

Standard

Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. / Kreuter, Michael; Bonella, Francesco; Blank, Nobert; Riemekasten, Gabriela; Müller-Ladner, Ulf; Henes, Jörg; Siegert, Elise; Günther, Claudia; Kötter, Ina; Pfeiffer, Christiane; Schmalzing, Marc; Zeidler, Gabriele; Korsten, Peter; Susok, Laura; Juche, Aaron; Worm, Margitta; Jandova, Ilona; Ehrchen, Jan; Sunderkötter, Cord; Keyßer, Gernot; Ramming, Andreas; Schmeiser, Tim; Kreuter, Alexander; Kuhr, Kathrin; Lorenz, Hanns-Martin; Moinzadeh, Pia; Hunzelmann, Nicolas.

In: RHEUMATOLOGY, Vol. 62, No. 9, 01.09.2023, p. 3067-3074.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kreuter, M, Bonella, F, Blank, N, Riemekasten, G, Müller-Ladner, U, Henes, J, Siegert, E, Günther, C, Kötter, I, Pfeiffer, C, Schmalzing, M, Zeidler, G, Korsten, P, Susok, L, Juche, A, Worm, M, Jandova, I, Ehrchen, J, Sunderkötter, C, Keyßer, G, Ramming, A, Schmeiser, T, Kreuter, A, Kuhr, K, Lorenz, H-M, Moinzadeh, P & Hunzelmann, N 2023, 'Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis', RHEUMATOLOGY, vol. 62, no. 9, pp. 3067-3074. https://doi.org/10.1093/rheumatology/kead023

APA

Kreuter, M., Bonella, F., Blank, N., Riemekasten, G., Müller-Ladner, U., Henes, J., Siegert, E., Günther, C., Kötter, I., Pfeiffer, C., Schmalzing, M., Zeidler, G., Korsten, P., Susok, L., Juche, A., Worm, M., Jandova, I., Ehrchen, J., Sunderkötter, C., ... Hunzelmann, N. (2023). Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. RHEUMATOLOGY, 62(9), 3067-3074. https://doi.org/10.1093/rheumatology/kead023

Vancouver

Kreuter M, Bonella F, Blank N, Riemekasten G, Müller-Ladner U, Henes J et al. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. RHEUMATOLOGY. 2023 Sep 1;62(9):3067-3074. https://doi.org/10.1093/rheumatology/kead023

Bibtex

@article{c43e8908fd24467099266980d3b6d82e,
title = "Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis",
abstract = "OBJECTIVES: Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD).METHODS: We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan-Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death.RESULTS: It was found that 2693/4306 (63%) registered patients with SSc and 1204/1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n = 760 vs 90.8% (87.9-93.8); n = 290] and after 5 years [91.4% (89.2-93.8); n = 357 vs 70.9% (65.2-77.1); n = 106; P < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6-97.3); n = 745 vs 86.4% (82.9-90.1); n = 278] and after 5 years [66.8% (63.0-70.8); n = 286 vs 45.9% (39.6-53.2); n = 69; P < 0.0001].CONCLUSION: GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding.",
author = "Michael Kreuter and Francesco Bonella and Nobert Blank and Gabriela Riemekasten and Ulf M{\"u}ller-Ladner and J{\"o}rg Henes and Elise Siegert and Claudia G{\"u}nther and Ina K{\"o}tter and Christiane Pfeiffer and Marc Schmalzing and Gabriele Zeidler and Peter Korsten and Laura Susok and Aaron Juche and Margitta Worm and Ilona Jandova and Jan Ehrchen and Cord Sunderk{\"o}tter and Gernot Key{\ss}er and Andreas Ramming and Tim Schmeiser and Alexander Kreuter and Kathrin Kuhr and Hanns-Martin Lorenz and Pia Moinzadeh and Nicolas Hunzelmann",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.",
year = "2023",
month = sep,
day = "1",
doi = "10.1093/rheumatology/kead023",
language = "English",
volume = "62",
pages = "3067--3074",
journal = "RHEUMATOLOGY",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis

AU - Kreuter, Michael

AU - Bonella, Francesco

AU - Blank, Nobert

AU - Riemekasten, Gabriela

AU - Müller-Ladner, Ulf

AU - Henes, Jörg

AU - Siegert, Elise

AU - Günther, Claudia

AU - Kötter, Ina

AU - Pfeiffer, Christiane

AU - Schmalzing, Marc

AU - Zeidler, Gabriele

AU - Korsten, Peter

AU - Susok, Laura

AU - Juche, Aaron

AU - Worm, Margitta

AU - Jandova, Ilona

AU - Ehrchen, Jan

AU - Sunderkötter, Cord

AU - Keyßer, Gernot

AU - Ramming, Andreas

AU - Schmeiser, Tim

AU - Kreuter, Alexander

AU - Kuhr, Kathrin

AU - Lorenz, Hanns-Martin

AU - Moinzadeh, Pia

AU - Hunzelmann, Nicolas

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - OBJECTIVES: Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD).METHODS: We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan-Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death.RESULTS: It was found that 2693/4306 (63%) registered patients with SSc and 1204/1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n = 760 vs 90.8% (87.9-93.8); n = 290] and after 5 years [91.4% (89.2-93.8); n = 357 vs 70.9% (65.2-77.1); n = 106; P < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6-97.3); n = 745 vs 86.4% (82.9-90.1); n = 278] and after 5 years [66.8% (63.0-70.8); n = 286 vs 45.9% (39.6-53.2); n = 69; P < 0.0001].CONCLUSION: GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding.

AB - OBJECTIVES: Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD).METHODS: We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan-Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death.RESULTS: It was found that 2693/4306 (63%) registered patients with SSc and 1204/1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n = 760 vs 90.8% (87.9-93.8); n = 290] and after 5 years [91.4% (89.2-93.8); n = 357 vs 70.9% (65.2-77.1); n = 106; P < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6-97.3); n = 745 vs 86.4% (82.9-90.1); n = 278] and after 5 years [66.8% (63.0-70.8); n = 286 vs 45.9% (39.6-53.2); n = 69; P < 0.0001].CONCLUSION: GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding.

U2 - 10.1093/rheumatology/kead023

DO - 10.1093/rheumatology/kead023

M3 - SCORING: Journal article

C2 - 36708008

VL - 62

SP - 3067

EP - 3074

JO - RHEUMATOLOGY

JF - RHEUMATOLOGY

SN - 1462-0324

IS - 9

ER -